Clearmind Successfully Completes Patient Recruitment for the First Alcohol Use Disorder Cohort of its CMND-100 Phase I/IIa Clinical Trial
Stocks in this Quantisnow insightHealth Care
Historical context for CMND
Across the 30 sessions after earlier CMND headlines, the stock closed higher 10 times and lower 19 times, with a median move of 6.1% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | CMND | SPY |
|---|---|---|---|
| Oct 12, 2026 | Clearmind: Charging Robotics Launches Next-Generation Automated EV-Charging Technology for Robotaxis and Autonomous Fleets | -0.6% | -0.1% |
| Oct 8, 2026 | Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder | +0.0% | -0.4% |
| Oct 7, 2026 | Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA | +13.0% | -0.2% |
| Sep 23, 2026 | Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations | +8.8% | -0.7% |
| Sep 17, 2026 | Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C. | +6.5% | +1.1% |
| Sep 11, 2026 | Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial | -1.5% | +0.9% |
Quantisnow market dataNASDAQ
CMND
Clearmind Medicine Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for CMND
Full CMND profile on Quantisnow Follow CMND and get a push notification the moment its next story breaks.